Answers are grounded in this paper and cite their sources.
Shows BDNF mitigates oxidative stress in Parkinson's disease models, suggesting new therapeutic strategies.
Parkinson's disease, a neurodegenerative disorder, is characterized by the degeneration of dopaminergic neurons and the accumulation of α-synuclein, both of which are aggravated by oxidative stress. This study utilized rotenone-treated SH-SY5Y cells to assess cell viability, ROS levels, and mitochondrial function. RNA-seq, mass spectrometry, and Co-IP analyses identified BDNF-regulated proteins linked to oxidative stress. In rotenone-induced PD mice, evaluations were made of motor performance, neuronal degeneration, and protein expression. Results showed that a 36-h exposure to 0.5 µM rotenone significantly increased ROS production, impaired mitochondrial function, and caused cellular damage in SH-SY5Y cells, effects which were reversed by BDNF overexpression. In mice, BDNF overexpression in the substantia nigra pars compacta alleviated PD-like symptoms. Co-IP analysis showed that BDNF modulates NRF2 and its associated proteins via HSP90AA1. These findings demonstrate that BDNF alleviates rotenone-induced oxidative stress in PD models through the HSP90AA1/NRF2 pathway, offering critical insights into the pathogenesis and potential therapeutic strategies for Parkinson's disease.
No takes yet. Share an insight, caveat, or question.
Xie et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: